Hyperplasie de l'endomètre

Endometrial hyperplasia is a condition of excessive proliferation of the cells of the endometrium, or inner lining of the uterus. Most cases of endometrial hyperplasia result from high levels of estrogens, combined with insufficient levels of the progesterone-like hormones which ordinarily counteract estrogen's proliferative effects on this tissue. This may occur in a number of settings, including obesity, polycystic ovary syndrome, estrogen producing tumours (e.g. granulosa cell tumour) and certain formulations of estrogen replacement therapy. Endometrial hyperplasia with atypia is a significant risk factor for the development or even co-existence of endometrial cancer, so careful monitoring and treatment of women with this disorder is essential. Like other hyperplastic disorders, endometrial hyperplasia initially represents a physiological response of endometrial tissue to the growth-promoting actions of estrogen. However, the gland-forming cells of a hyperplastic endometrium may also undergo changes over time which predispose them to cancerous transformation. Several histopathology subtypes of endometrial hyperplasia are recognisable to the pathologist, with different therapeutic and prognostic implications. The most commonly used classification system for endometrial hyperplasia is the World Health Organization (WHO) system, which previously had four categories: simple hyperplasia without atypia, complex hyperplasia without atypia, simple atypical hyperplasia and complex atypical hyperplasia. In 2014, the WHO updated the classification system and removed the distinction between simple or complex hyperplasia, instead only on presence or absence of atypia. Endometrial hyperplasia (simple or complex) - Irregularity and cystic expansion of glands (simple) or crowding and budding of glands (complex) without worrisome changes in the appearance of individual gland cells. In one study, 1.6% of patients diagnosed with these abnormalities eventually developed endometrial cancer.

À propos de ce résultat

Cette page est générée automatiquement et peut contenir des informations qui ne sont pas correctes, complètes, à jour ou pertinentes par rapport à votre recherche. Il en va de même pour toutes les autres pages de ce site. Veillez à vérifier les informations auprès des sources officielles de l'EPFL.

Publications associées (2)

Proteome-Wide Effect of 17-beta-Estradiol and Lipoxin A(4) in an Endometriotic Epithelial Cell Line

Endometriosis affects approximately 10% of women of reproductive age. This chronic, gynecological inflammatory disease results in a decreased quality of life for patients, with the main symptoms including chronic pelvic pain and infertility. The steroid ho ...

Frontiers Media Sa2016

Background and Objectives Endometriumablation provides an alternative treatment modality to hysterectomy for dysfunctional uterine bleeding (DUB). Its feasibility was demonstrated in animal studies. The purpose of this study was the evaluation of histol ...

Wiley-Blackwell2003

Concepts associés (11)

Séances de cours associées (1)

Hormone replacement therapy

Hormone replacement therapy (HRT), also known as menopausal hormone therapy or postmenopausal hormone therapy, is a form of hormone therapy used to treat symptoms associated with female menopause. These symptoms can include hot flashes, vaginal atrophy, accelerated skin aging, vaginal dryness, decreased muscle mass, sexual dysfunction, and bone loss or osteoporosis. They are in large part related to the diminished levels of sex hormones that occur during menopause. Estrogens and progestogens are the main hormone drugs used in HRT.

Cancer de l'endomètre

Le 'cancer de l'endomètre, appelé aussi cancer du corps utérin', est le cancer qui se développe à partir de l'endomètre qui est le tissu de l'utérus où se produit la nidation. Au sens strict, ce terme générique désigne l'ensemble des tumeurs malignes (cancer) de l'endomètre. Dans l'usage, il désigne l'adénocarcinome de l'endomètre. Il ne doit pas être confondu avec le cancer du col de l'utérus car les causes et les caractéristiques épidémiologiques de ces deux cancers sont différentes.

Raloxifène

Le raloxifène est un SERM (Selective Estrogen Receptor Modulator) comme le bazédoxifène. Il est utilisé dans le cadre de traitements hormonaux de substitution, utiles à la prévention et traitement de l'ostéoporose. Il peut également être utilisé pour diminuer le risque de cancer du sein. Une diminution du taux d'œstrogène est responsable de la fragilisation de l'os. Un traitement classique pour prévenir l'ostéoporose consiste à administrer un traitement hormonal substitutif.

Cycle menstruel: Phases et régulation hormonale

Explore les phases du cycle menstruel, la régulation hormonale et le développement humain.